ArticlePregnancy (Hoboken, N.J.)2025
Safety of prostaglandins in the peripartum period in case of sickle-cell disease: A multicenter cohort study.
Article in Pregnancy (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pregnancies with sickle-cell disease are at high risk of maternal, obstetrical, and fetal complications, for which prostaglandins are often indicated to induce labor or to treat postpartum hemorrhage. There is concern that prostaglandin use may increase the risk of vaso-occlusion, but to date no clinical study has yet assessed this risk. Our objective was to assess the safety of prostaglandins during delivery and postpartum in women with sickle-cell disease. Method: A retrospective multicenter cohort study in 10 tertiary university-affiliated centers in France, including all women with sickle-cell disease (S/S, S/C, or S/β-thalassemia) delivering in the centers. Methods: We compared pregnancies with and without exposure to prostaglandins, overall and specifically according to whether prostaglandins were used for labor induction or for postpartum hemorrhage. The main outcome was the occurrence of vaso-occlusive crisis and/or thromboembolism, within 7 days after delivery. Secondary outcomes were vaso-occlusive crises requiring intravenous morphine and/or intensive care admission. Results: Prostaglandins were used in 114/411 pregnancies (27.7%). In 106/411 (25.8%), they were used to induce labor, with Prostaglandin E2 (dinoprostone gel or pessary) for 95 patients and misoprostol for 11 patients. The incidence of postpartum hemorrhage was 60/411 (14.6%), and 11 cases required second-line therapy with prostaglandins; sulprostone was used as per French practice guidelines. The incidence of vaso-occlusive crises and/or venous thromboembolism in the postpartum did not differ between patients exposed and not exposed to prostaglandins (14/114 (12.2%) vs. 34/293 (11.6%), respectively; Conclusion: The use of prostaglandins in patients with sickle-cell disease for labor induction or for postpartum hemorrhage appeared safe, within the limitations of a retrospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.